CD 44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer-Reference-Cited by-同舟云学术

CD 44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer

Published:2015-09-21 Issue:10 Volume:106 Page:1421-1428
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tjhay Francisca¹,Motohara Takeshi¹,Tayama Shingo¹,Narantuya Dashdemberel¹,Fujimoto Koichi¹,Guo Jianying¹,Sakaguchi Isao¹,Honda Ritsuo¹,Tashiro Hironori²,Katabuchi Hidetaka¹

Affiliation:

1. Department of Obstetrics and Gynecology Faculty of Life Sciences Kumamoto University Kumamoto City Kumamoto Japan

2. Department of Maternal‐Newborn Nursing Kumamoto University Kumamoto City Kumamoto Japan

Funder

Japan Society for the promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12765

Reference38 articles.

1. Cancer statistics, 2014

2. Beyond chemotherapy: targeted therapies in ovarian cancer

3. Ovarian Cancer Development and Metastasis

4. The biology of ovarian cancer: new opportunities for translation

5. Mechanism and biological significance of CD44 cleavage

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the intricacies: Exploring the complex interplay between platelets and ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer;Frontiers in Oncology;2024-03-25

3. Defining the Role of Metastasis-Initiating Cells in Promoting Carcinogenesis in Ovarian Cancer;Biology;2023-12-05

4. CD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomas;Clinical and Experimental Medicine;2023-09-25

5. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28